Sandoz Enters Canada With First Denosumab Biosimilar

Jubbonti Is Canada’s First and Only Denosumab Biosimilar For Osteoporosis

 
• By Urtė Fultinavičiūtė
  
Red pin on Canada on the map
Denosumab key patents will expire in 2025 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products